BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health. Since its first investments in 2003, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
Opsidio is a biotechnology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company specializes in developing monoclonal antibodies aimed at treating fibrotic and remodeling diseases, as well as allergic conditions. Opsidio's innovative antibodies specifically target a unique form of the Stem Cell Factor, which plays a crucial role in the cascade of profibrotic cytokines. This targeted approach enables healthcare providers to address various serious conditions, including idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, ultimately improving treatment options for affected patients.
Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.
Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.
CytoVas LLC is a life science company based in Philadelphia, Pennsylvania, that specializes in developing an innovative informatics platform, CLOUD CYTOMICS. This platform is designed to analyze flow cytometry data, providing clinicians and drug developers with actionable insights on novel cellular markers related to disease progression and individual treatment responses. By automating data collection and interpretation, CLOUD CYTOMICS enables rapid identification of cellular biomarkers, facilitating critical decision-making in the development of targeted therapies. The technology is applicable across various therapeutic areas, including cardiovascular disease, type 2 diabetes, Alzheimer’s, and more. Founded by experts in computational biology and flow cytometry from the University of Pennsylvania, CytoVas is supported by significant investments from organizations such as the American Heart Association and the National Institutes of Health, as well as a partnership with Becton Dickinson Biosciences. The company continues to explore the potential of its platform in diverse medical research fields.
HueDx is a developer of point-of-care diagnostic tests aimed at enhancing patient care. The company utilizes innovative paper- or wax-based microfluidics technology to deliver rapid, quantitative assay-based tests that provide quick results across a range of applications. By eliminating the need for physical devices and software, HueDx's platform streamlines the test development and launch process, making diagnostics more accessible and cost-effective. This approach not only improves transparency for clinicians but also facilitates immediate patient results, ultimately contributing to a more efficient healthcare delivery system.
TalexMedical is the proud producer of Infantear – a revolutionary Class I medical device for the treatment of external ear deformities in newborns. InfantEar is a simple, yet elegant, nonsurgical ear molding system, applied in the outpatient setting, replacing the costly, labor intensive surgical ear procedure. The unique, fully customizable device is made of soft materials for increased comfort. Targeted primarily to pediatricians, who can recognize and treat the ear anomaly with one two-week treatment applied to a patient in the first three weeks of life, avoiding the delayed and costly external referral with specialists. This helps us to achieve the Triple Aim of Healthcare – improved results, increased patient satisfaction and decreased cost.
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.
Keriton LLC is a provider of a pumped breast milk management system specifically designed for neonatal intensive care units (NICUs). Based in Philadelphia, Pennsylvania, the company offers a comprehensive platform that enhances patient safety and streamlines nursing workflows. This system enables healthcare professionals to track milk-bottle inventory, manage feeding orders, and handle first-in-first-out (FIFO) bottle flow, including notifications for expiry dates and misfeed alerts. The platform also facilitates real-time insights into lactating mothers' milk production patterns and includes a media-sharing feature for nurses to communicate with mothers by sharing photos and videos of their babies. With a track record of managing over 1.5 million feeds and preventing nearly 30,000 errors, Keriton's solution aims to improve health outcomes and reduce the cognitive burden on hospital staff. Since its incorporation in 2016, Keriton has been deployed in numerous larger enterprise health systems, demonstrating its effectiveness in enhancing the care provided to infants in NICUs.
Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.
Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.
Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
Penn State Health is a multi-hospital health system that serves patients and communities across Central Pennsylvania. It includes the Milton S. Hershey Medical Center, a 551-bed Level I regional trauma center recognized for its expertise in complex adult and pediatric cases. As the region's only academic medical center, it is closely affiliated with the Penn State College of Medicine and houses the Children's Hospital at Penn State Health. The medical center has achieved ANCC Magnet Recognition, reflecting its dedication to fostering a supportive professional environment for staff and delivering high-quality patient care.
Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company develops Theo, a digital healthcare advisory platform designed to assist patients in identifying health and behavioral risks. The platform actively engages patients by providing programs and interventions to help them manage these risks. By capturing essential patient data at the time of care, Noble.MD facilitates value-based reimbursement and aligns the interests of providers and payers, enhancing the processes of risk identification, coding, and management.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.
Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.
Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
RiboNova Inc. is a biopharmaceutical company based in Wynnewood, Pennsylvania, focused on developing small molecule drugs aimed at treating serious rare diseases, including certain cancers and mitochondrial diseases. Incorporated in 2011, RiboNova leverages a drug discovery platform that targets defective transfer RNA molecules, which play a critical role in cellular function. The company's innovative approach centers on precision medicines that address ribonucleic acid anomalies, providing healthcare professionals with new treatment options for patients suffering from genetically confirmed mitochondrial conditions and select cancer types. RiboNova operates within the Lankenau Institute for Medical Research near Philadelphia, emphasizing its commitment to advancing therapeutic solutions in the field of rare diseases.
Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.
Allevi develops innovative tools for designing and engineering 3D tissues, focusing on bioprinting technology. The company offers desktop 3D bioprinters that allow users to create functional three-dimensional living tissues using various biomaterials and cell lines. Additionally, Allevi provides bioinks made from collagen and hyaluronic acid, which are available for purchase online. Their cloud-based platform, Bioprint Online, enables users to design complex structures, define materials, and monitor the printing process. Allevi's products serve a diverse clientele, including researchers in tissue engineering, regenerative medicine, and cell biology, as well as industrial and pharmaceutical companies for drug testing and development, and educators. Established in 2014 and based in Philadelphia, Pennsylvania, Allevi was formerly known as BioBots, Inc.
Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.
TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.
Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.
Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.
OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
BioDetego is focused on advancing cancer treatment through its innovative biomarker test, VASPfore, which is designed to optimize the selection of chemotherapy protocols. This test assesses the metastatic risk in colorectal cancer patients, allowing healthcare providers to identify high-risk individuals who are likely to benefit from chemotherapy while sparing low-risk patients from unnecessary and potentially harmful treatments. By providing actionable insights, VASPfore aims to improve patient outcomes and enhance the efficiency of cancer management. BioDetego anticipates significant cost savings for payors, estimating reductions of over $150 million annually in treatment expenses. The company is led by David Zuzga, Ph.D., and Giovanni M. Pitari, M.D., Ph.D., both of whom bring extensive expertise in cell and molecular biology and translational oncology, respectively.
HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.
InfraScan is a medical device company that invented and distributes hand-held diagnostic devices for head injury and stroke assessment based on Near-Infrared (NIR) technology. The Infrascanner enables clinicians to effectively, conveniently, and accurately detect intracranial bleeding in patients with head trauma. Intracranial hematomas are an important and, if diagnosed early, treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries, and 40% of them have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. The Office of Naval Research funded the company in May, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multi-center clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA.
Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
Microbiota
Seed Round in 2013
Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.
Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.
OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.
Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.
Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in developing and commercializing an innovative atomization technology that generates a high volume of micron-sized droplets using low-pressure gas and liquid. This technology is designed for a diverse array of industrial applications, including aircraft fire suppression, chemical processing, emission control, turbine inlet cooling, and decontamination. Additionally, it serves sectors such as artificial snow production and cooling systems. By leveraging its unique atomization capabilities, Life Mist Technologies aims to enhance existing processes and provide effective solutions to various industrial challenges. The company has been operational since its incorporation in 2004.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.
Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.
Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.
Anakim
Seed Round in 2012
Anakim Biologics is developing efficiencies and improvements in biologics manufacturing.
Treventis Corporation specializes in developing small molecule drugs aimed at treating and preventing protein misfolding diseases, particularly focusing on tauopathies related to Alzheimer’s disease. The company employs a proprietary discovery engine called Common Conformational Morphology (CCM), which integrates advanced in silico modeling with extensive expertise in drug development across various biological systems. This innovative approach allows Treventis to identify druggable active sites in misfolded protein targets, facilitating the rational design of therapeutic compounds. The lead program is centered around anti-misfolding small molecules that target tau proteins, while additional CCM-driven initiatives are underway in oncology and other neurodegenerative disorders, highlighting the versatility of their technology platform. The drugs developed by Treventis aim to effectively neutralize misfolded proteins, potentially blocking the progression of amyloid toxicity and offering a treatment option for Alzheimer’s patients with minimal side effects.
Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Imiplex LLC is a biotechnology company based in Bristol, Pennsylvania, that specializes in developing protein-based nanotechnology for applications in biosensors, biomaterials, and targeted therapeutic and diagnostic agents. Founded in 2003, Imiplex has created a platform known as TriPol, which consists of modular components engineered from proteins. This technology leverages the unique properties of proteins, such as their ability to self-assemble with atomic precision and their structural diversity, to construct various nanostructures. These engineered protein nanostructures support early diagnosis and treatment of diseases, including cancer, diabetes, and neurodegenerative disorders like Alzheimer's disease.
COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.
CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.
Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.
RMH Sciences
Seed Round in 2012
RMH Sciences aims to commercialize newly discovered antibiotics by Dr. Harvey Rubin, University of Pennsylvania Professor of Medicine. One of RMH’s most promising ventures focuses on creating antibiotics to combat hospital acquired bacterial pathogens, a largely unmet need in the current marketplace.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Leversense, LLC intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Eagle Vision Pharmaceutical Corp. offers a novel, clinical-stage, molecular imaging opportunity that enhances the powerful potential of widely available Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of chronic human disease (“Magnetic PET”). SeeMoreTM (EVP1001), a patented, first-in-class, intravenous, manganese-based, intracellular agent that targets metabolically active cells, capitalizes on the high resolution tissue discrimination of MRI to provide superior diagnostic accuracy and earlier assessment of response to therapy for improved patient management. EVP1001 distinguishes healthy from abnormal tissue in a single, noninvasive exam that avoids radiation and radioactive agents. Preclinical and clinical results have validated the technology for broad applications including evaluation of cancer, chronic liver disease and heart disease. Currently, a world-class medical center is conducting advanced clinical trials using EVP1001 to evaluate stem cell therapy for the heart.
Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.
Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.
Formae, Inc. is a company specializing in arthroscopic joint resurfacing and replacement technologies, founded in 2006 and based in Paoli, Pennsylvania. It develops innovative products, including a biocompatible implant known as ArthroPad, which provides a minimally invasive surgical solution for replacing damaged cartilage in arthritic joints. The company's focus is on addressing conditions such as arthritis and joint destruction, utilizing proprietary synthetic cartilage to enhance patient outcomes in joint health.
Phoenix S&T, Inc. specializes in the design, development, and supply of nanospray and microspray systems aimed at advancing life science research and drug discovery. The company offers a range of products, including the Nimbus and pneu-Nimbus NanoLC systems, which are utilized for ionization in liquid chromatography and mass spectrometry experiments. Additionally, it provides micro-molded devices, 3D microfluidic devices, column heaters, coolers, and various emitters, catering to applications in proteomics, biomarkers, and direct infusion. Phoenix S&T serves a diverse customer base primarily in Europe and China. Founded in 2001, the company operates from its headquarters in Elkton, Maryland.
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.
Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.